Summary of the characteristics of individual NRs, their gene expression changes with time on imatinib, and disease progression
Patient ID . | Disease phase . | hOCT1 . | ABCA2 . | ABCG2 . | ABCB1 . | KM . | Days to progression . | Disease progression . |
|---|---|---|---|---|---|---|---|---|
| 1 | CP | – | – | ∼ | ∼ | nil | 1493 | CE |
| 2 | CP | – | – | + | + | nil | NA | none |
| 3 | AP | – | – | ∼ | + | nil | 987 | CE |
| 4 | CP | – | – | + | ∼ | nil | NA | none |
| 5 | CP | – | – | ∼ | ∼ | nil | NA | none |
| 6 | CP | + | ∼ | + | ∼ | G250E | 167 | AP |
| 7 | CP | – | – | – | ∼ | nil | 297 | MBC |
| 8 | CP | + | – | – | – | nil | NA | none |
| 9 | CP | ∼ | + | ∼ | – | nil | NA | none |
| 10 | CP + CE | + | + | + | + | nil | NA | none |
| 11 | CP | + | + | ∼ | ∼ | nil | NA | none |
| 12 | CP | + | + | ∼ | ∼ | nil | NA | none |
| 13 | CP | ∼ | + | + | ∼ | nil | 941 | CE |
| 14 | CP | ∼ | ∼ | ∼ | ∼ | nil | NA | none |
| 15 | CP + CE | + | + | ∼ | ∼ | Y253F | 1076 | CE |
Patient ID . | Disease phase . | hOCT1 . | ABCA2 . | ABCG2 . | ABCB1 . | KM . | Days to progression . | Disease progression . |
|---|---|---|---|---|---|---|---|---|
| 1 | CP | – | – | ∼ | ∼ | nil | 1493 | CE |
| 2 | CP | – | – | + | + | nil | NA | none |
| 3 | AP | – | – | ∼ | + | nil | 987 | CE |
| 4 | CP | – | – | + | ∼ | nil | NA | none |
| 5 | CP | – | – | ∼ | ∼ | nil | NA | none |
| 6 | CP | + | ∼ | + | ∼ | G250E | 167 | AP |
| 7 | CP | – | – | – | ∼ | nil | 297 | MBC |
| 8 | CP | + | – | – | – | nil | NA | none |
| 9 | CP | ∼ | + | ∼ | – | nil | NA | none |
| 10 | CP + CE | + | + | + | + | nil | NA | none |
| 11 | CP | + | + | ∼ | ∼ | nil | NA | none |
| 12 | CP | + | + | ∼ | ∼ | nil | NA | none |
| 13 | CP | ∼ | + | + | ∼ | nil | 941 | CE |
| 14 | CP | ∼ | ∼ | ∼ | ∼ | nil | NA | none |
| 15 | CP + CE | + | + | ∼ | ∼ | Y253F | 1076 | CE |
KM indicates kinase mutation after imatinib; CP, chronic phase; –, at least a halving in gene expression with time on imatinib; CE, clonal evolution; +, at least a doubling in gene expression with time on imatinib; AP, accelerated phase; MBC, myeloid blast crisis; and CP + CE, chronic phase with evidence of clonal evolution. ∼ indicates no change in gene expression with time on imatinib; nil, no kinase mutation detected; NA, not applicable; and none, no disease progression during follow up.